Stoneridge (SRI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Voting matters and shareholder proposals
Shareholders are asked to approve the 2025 Long-Term Incentive Plan, which would provide 726,000 shares for future grants and include non-employee directors as participants.
The Board intends to terminate the Directors' Restricted Shares Plan if the 2025 Plan is approved, consolidating all future director equity awards under the new plan.
Executive compensation and say-on-pay
As of March 31, 2025, there are 1,767,066 shares subject to outstanding equity awards, including restricted stock units, restricted shares, and performance-based share awards.
No stock options or stock appreciation rights are outstanding as of March 31, 2025.
Performance share awards are reserved at maximum or target performance levels depending on grant date.
Board of directors and corporate governance
The Board plans to discontinue the Directors' Restricted Shares Plan and transition director equity awards to the 2025 Long-Term Incentive Plan, pending shareholder approval.
Latest events from Stoneridge
- 2025 outperformed end markets with 69%–70% MirrorEye growth and strong 2026 targets.SRI
Q4 202512 Mar 2026 - Q2 2024 saw margin gains, EPS growth, and updated guidance as key tech launches accelerated.SRI
Q2 20242 Feb 2026 - Control Devices sold for $59M to focus on advanced electronics and reduce debt.SRI
Status update2 Feb 2026 - MirrorEye and Smart 2 drive growth through innovation, safety, and regulatory compliance.SRI
CL King’s 22nd Annual Best Ideas Conference 202420 Jan 2026 - Q3 sales and earnings declined, but cash flow and MirrorEye adoption showed improvement.SRI
Q3 202417 Jan 2026 - Growth driven by MirrorEye, Smart 2, and operational improvements despite market softness.SRI
Stephens 26th Annual Investment Conference | NASH202413 Jan 2026 - MirrorEye/Mirai and Smart 2 growth offset market declines, driving margin and cash flow gains.SRI
Q4 202426 Dec 2025 - Margin gains and record product sales drive Q1, with guidance reaffirmed despite net loss.SRI
Q1 202524 Dec 2025 - 2025 proxy covers director elections, auditor ratification, compensation, and new LTIP.SRI
Proxy Filing2 Dec 2025